Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Avelumab + Tipapkinogene sovacivec|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Avelumab||Bavencio||MSB0010718C||Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 96||Bavencio (avelumab) is a monoclonal antibody binds to human immunosuppressive ligand programmed death-ligand 1 (PD-L1, CD274) and blocks protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in adult and pediatric patients of 12 years or older with metastatic Merkel cell carcinoma, as maintenance therapy in locally advanced or metastatic urothelial carcinoma (UC), in locally advanced or metastatic UC that progressed following chemotherapy, and in combination with axitinib as first-line therapy in advanced renal cell carcinoma (FDA.gov).|
|Tipapkinogene sovacivec||MVA-HPV16E6/E7-IL2|R3484|RG3484|RO5217790|TG 4001|TG-4001|TG4001||Tipapkinogene sovacivec is a modified vaccinia virus Ankara (MVA)-based cancer vaccine, engineered to express the cytokine IL-2 and non-oncogenic versions of the human papilloma virus 16 (HPV16) proteins E6 and E7, which may lead to immune response and antitumor activity against HPV16 positive cancers (Annals of Oncology 30 Suppl 5 (2019): v494-v495; PMID: 30955915).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03260023||Phase Ib/II||Avelumab Avelumab + Tipapkinogene sovacivec||Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers||Recruiting||USA | FRA | ESP||0|